Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2023

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

Commission File No. 000-53230

REGENEREX PHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada		98-0479983
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

5348 Vegas Drive #177

Las Vegas, NV 89108

(Address of principal executive offices)

877-761-7479

Registrant’s telephone number, including area code

Peptide Technologies, Inc.

(Former name or former address, if changed since last report.)

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:

Yes [X ] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-Accelerated filer	[ ]	Smaller reporting company	[X]
		Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act).

Yes [ ] No [X]

Securities registered pursuant to Section 12(b) of the Act: None

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at February 5, 2024
Common stock, $0.001 par value		277,995,910

“Explanatory Note Regarding Forward-Looking Statements:”

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

	•	our ability to add new customers;
	•	the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows;
	•	the potential benefits of and our ability to maintain our relationships, and establish or maintain future collaborations or strategic relationships or obtain additional funding;
	•	our marketing capabilities and strategy;
	•	our ability to maintain a cost-effective program;
	•	our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;
	•	our competitive position, and developments and projections relating to our competitors and our industry;
	•	our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
	•	the impact of laws and regulations.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

REGENEREX PHARMA, INC.

INDEX TO FORM 10-Q FILING

FOR THE NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022

TABLE OF CONTENTS

		PAGE
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	1
	Balance Sheets	1
	Statements of Operations	2
	Statements of Cash Flows	3
	Statements of Stockholders’ Deficit	4
	Notes to Financial Statements	5
Item 2.	Management Discussion & Analysis of Financial Condition and Results of Operations	12
Item 3	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 4.	Mining Safety Disclosures	19
Item 5	Other Information	19
Item 6.	Exhibits	19

CERTIFICATIONS

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act
32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

REGENEREX PHARMA, INC.

BALANCE SHEETS

(UNAUDITED)

		December 31, 2023			March 31, 2023
ASSETS

Current Assets
Cash and equivalents	$	7,856		$	1,135
Prepaid expenses		1,423			—
Total Current Assets		9,279			1,135

Website, net of accumulated amortization of $28,557 and $26,397, respectively		2,043			4,203
Furniture and computer equipment, net of accumulated amortization of $1,170 and $197, respectively		6,527			1,201
Right of use asset		834,293			—
Total Assets	$	852,142		$	6,539

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities
Accounts payable	$	78,950		$	75,145
Related party advances		4,757			131,887
Accrued compensation		414,962			221,192
Other accrued liabilities		83,227			125,787
Current portion of notes payable to shareholder		322,246			222,771
Current portion of notes payable to related parties		103,500			—
Current portion of notes payable		2,400,000			—
Current portion of lease liabilities		152,046			—
Total Current Liabilities		3,559,688			776,782

Notes payable to shareholder, net of current portion		260,788			314,704
Notes payable to related parties, net of current portion		—			38,000
Notes payable, net of current portion		184,232			—
Lease liabilities, net of current portion		723,497			—
Total Liabilities		4,728,205			1,129,486

Commitments and Contingencies (Note 7)		-			-

Stockholders’ Deficit
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,945,910 and 277,112,660 issued and outstanding at December 31, 2023 and March 31, 2023, respectively		277,946			277,113
Additional paid-in capital		1,169,014			671,963
Accumulated deficit		(5,323,023	)		(2,072,023	)
Total Stockholders’ Deficit		(3,876,063	)		(1,122,947	)
Total Liabilities and Stockholders’ Deficit	$	852,142			6,539

The accompanying notes are an integral part of these unaudited financial statements.

REGENEREX PHARMA, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)


		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2023			2022			2023			2022

Operating Expenses
General and administrative	$	239,384		$	29,102		$	785,481		$	67,892
Research and development		—			—			2,400,000			—
Total Operating Expenses		239,384			29,102			3,185,481			67,892

Operating Loss		(239,384	)		(29,102	)		(3,185,481	)		(67,892	)

Other Income (Expense)
Interest expense		(20,219	)		(17,241	)		(58,526	)		(49,365	)
Foreign currency gain (loss)		(4,373	)		(3,057	)		(6,993	)		26,217
Total Other Income (Expense)		(24,592	)		(20,298	)		(65,519	)		(23,148	)

Net Loss	$	(263,976	)	$	(49,400	)	$	(3,251,000	)	$	(91,040	)

Basic and Diluted Loss per Common Share	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.00	)
Weighted Average Number of Common Shares Outstanding		277,919,497			227,112,660			277,539,983			277,112,660

The accompanying notes are an integral part of these unaudited financial statements.

REGENEREX PHARMA, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)


		For the Nine Months Ended
		December 31,
		2023			2022
Cash Flows from Operating Activities:
Net loss	$	(3,251,000	)	$	(91,040	)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization		3,133			2,598
Foreign currency adjustments		6,993			(26,217	)
Stock-based compensation		154,634			—
Research and development		2,400,000			—
Amortization of ROU assets, net of liabilities		41,250			—
Changes in operating assets and liabilities:
Prepaid expenses		(1,423	)		2,756
Accounts payable and accrued liabilities		253,300			38,763
Net cash used in operating activities		(393,113	)		(73,140	)

Cash Flows from Investing Activities:
Purchase of furniture and computer equipment		(6,299	)		(1,398	)
Net cash used in investing activities		(6,299	)		(1,398	)

Cash Flows from Financing Activities:
Related party advances		4,557			200
Proceeds from notes payable to shareholder		2,826			34,901
Proceeds from notes payable to related parties		105,000			40,500
Partial repayment of note payable to shareholder		(10,000	)		—
Partial repayment of note payable to related parties		(39,500	)		(2,500	)
Proceeds from sale of common stock and warrants		343,250			—
Net cash provided by financing activities		406,133			73,101

Increase (Decrease) in cash and equivalents		6,721			(1,437	)
Cash and cash equivalents, beginning of period		1,135			2,640
Cash and cash equivalents, end of period	$	7,856		$	1,203

Supplemental Cash Flow Information – Cash Paid For:
Income Taxes	$	—		$	—
Interest	$	—		$	—
Non-Cash Investing and Financing Activities:
Accrued interest converted into note payable	$	98,744		$	7,211
Operating lease, ROU asset and liabilities	$	953,535		$	—
Note payable issued for acquisition of intellectual property	$	2,400,000		$	—

The accompanying notes are an integral part of these unaudited financial statements.

REGENEREX PHARMA, INC.

STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)


	Common Stock
	Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Stockholders’ Deficit
Balance at March 31, 2022	277,112,660	$	277,113	$	671,963	$	(1,934,693	)	$	(985,617	)
Net loss	—		—		—		(41,640	)		(41,640	)
Balance at September 30, 2022	277,112,660	$	277,113	$	671,963	$	(1,976,333	)	$	(1,027,257	)
Balance at September 30, 2022	277,112,660	$	277,113	$	671,963	$	(1,976,333	)	$	(1,027,257	)
Net loss	—		—		—		(49,400	)		(49,400	)
Balance at December 31, 2022	277,112,660	$	277,113	$	671,963	$	(2,025,733	)	$	(1,076,657	)

Balance at March 31, 2023	277,112,660	$	277,113	$	671,963	$	(2,072,023	)	$	(1,122,947	)
Shares and warrants sold for cash	343,250		343		342,907		—			343,250
Stock-based compensation	460,000		460		132,928		—			133,388
Net loss	—		—		—		(2,987,024	)		(2,987,024	)
Balance at September 30, 2023	277,915,910	$	277,916	$	1,147,798	$	(5,059,047	)	$	(3,633,333	)
Balance at September 30, 2023	277,915,910	$	277,916	$	1,147,798	$	(5,059,047	)	$	(3,633,333	)
Stock-based compensation	30,000		30		21,216		—			21,246
Net loss	—		—		—		(263,976	)		(263,976	)
Balance at December 31, 2023	277,945,910	$	277,946	$	1,169,014	$	(5,323,023	)	$	(3,876,063	)

The accompanying notes are an integral part of these unaudited financial statements.

REGENEREX PHARMA, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 – NATURE OF OPERATIONS

Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.

On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15^th of the following month, for a period of 60 months. The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter the wound treatment market in the U.S.

Risks and Uncertainties

Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows.

The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.

The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

Operating results for the nine months ended December 31, 2023, are not necessarily indicative of the results that may be expected for the year ending March 31, 2024. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2023, have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2023, included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

NOTE 3 – GOING CONCERN

These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2023, it had excess liabilities over assets of $3,876,063. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company requires significant cash to launch its business and reduce its liabilities. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation.

We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran’s administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.

Earnings per Share

Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share.

During the three and nine-months ended December 31, 2023, the Company excluded the outstanding stock warrants from its calculation of earnings per share, as the warrants would be anti-dilutive. As at December 31, 2023 and 2022, the Company had common shares warrants outstanding of 2,432,250 and 0, respectively.

Website

Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2023 and 2022 was $723 and $723 and $2,160 and $1,016, respectively.

Furniture and Computer Equipment

Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the three and nine months ended December 31, 2023 and 2022 was $435 and $82 and $973 and $82, respectively. Significant betterments are capitalized while purchases under $500 are expensed as incurred.

Right of Use Assets and Lease Liabilities

The Company has active operating lease arrangements for office space, production equipment, and production facilities. The Company is required to make fixed minimum rent payments relating to its right to use the underlying leased asset. In accordance with the adoption of ASC 842, the Company recorded right-of-use assets and related lease liabilities for these leases as of December 2023.

The Company’s lease agreements do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an incremental borrowing rate of 10% to discount each of its lease liabilities based on the remining lease term.

Stock-Based Compensation

Stock-based compensation is measured at the grant date, based on the estimated fair value of the award. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. The fair value of each stock warrant is estimated on the date of grant using the Black-Scholes option valuation model. Share grants are measured based on the fair market value of the underlying stock on the grant date.

Research and Development

We incur research and development costs during the process of researching and developing additional technologies purchased and future manufacturing processes. Our research and development costs consist primarily of the purchase of additional intellectual property that we will use in the development of our planned product. We expense these costs as incurred until the resulting product has been completed, tested, and made ready for commercial use.

Recent Accounting Pronouncements

The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NOTE 5 – RELATED PARTY TRANSACTIONS

The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6).

On June 10, 2023, the Company has entered into an agreement with Woundcare Labs, LLC, a party related to the CFO and CEO of the company, to lease a plant and to lease equipment in Tennessee (see note 8).

Related Party Advances

The Company’s former Chief Financial Officer (“CFO”) had advanced the Company monies for operating expenses; no amounts were advanced during the periods presented. The advances were due on demand, but no later than June 30, 2023. The related party advances began to accrue interest at ten (10) percent per annum on July 1, 2019. During the nine months ended December 31, 2023, this note was transferred to a relative of the former CFO and was renewed upon maturity in the principal amount of $131,687 plus interest accrued as at June 30, 2023 in the amount of $52,545. Interest expense was $3,285 and $9,922 during the nine-month periods ended December 31, 2023 and 2022, respectively. This transaction is no longer considered related party in nature, and thus is included in notes payable in the accompanying balance sheet.

During the nine-month periods ended December 31, 2023 and 2022, the Company’s Chief Financial Officer (“CFO”) and the Company’s Chief Executive Officer (“CEO”) advanced the Company monies for operating expenses in the amount of $4,557 and $200, respectively.

The related party advances totaled $4,757 and $131,887 as of December 31, 2023, and March 31, 2023, respectively.

Notes Payable to Related Parties

During the year ended March 31, 2023, the Company’s CFO and the Company’s CEO advanced the Company monies for operating expenses in the amount of $40,500. Repayment during the nine-month period ended December 31, 2023 and 2022 was $38,000 and $2,500, respectively.

During the nine-month period ended December 31, 2023, the Company’s CFO and the Company’s CEO advanced the Company monies for operating expenses in the amount of $105,000. Repayment during the nine-month period ended December 31, 2023 was $1,500. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from May 2024 to June 11, 2024.

The related party notes payable totaled $103,500 and $38,000 as at December 31, 2023 and March 31, 2023. Interest expenses were $2,443 and $890 during the nine-month periods ended December 31, 2023 and 2022, respectively.

Note Payables to Shareholders

As at December 31, 2023 and March 31, 2023, the Company had various promissory notes with total outstanding principal balances of $583,034 and $537,475, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 20, 2024, to June 17, 2025.

During the nine months ended December 31, 2023, notes with principal amounts totaling approximately $154,000 ($200,500 Canadian dollars) that came due during the period were reissued in the total principal amount of approximately $185,000 ($240,600 Canadian dollars) which included the principal amount plus accrued interest of approximately $31,000 ($40,100 Canadian dollars).

During the nine months ended December 31, 2023, notes with principal amounts of $67,400 that came due during the period, were reissued in the principal amount of $82,735 which included the principal amount plus accrued interest of $15,335.

The reissued notes are unsecured, bear interest at 10% per annum, and have revised maturity dates ranging from April 11, 2024, to June 17, 2025.

During the nine-month period ended December 31, 2023, a shareholder was issued additional one (1) promissory note totaling approximately $2,800 ($3,844 Canadian dollars). This note is unsecured and bear interest at ten (10) percent per annum with principal and interest due twelve (12) months after the date of issue.

Accrued interest was $67,537 and $51,892 as of December 31, 2023 and March 31, 2023, respectively, which is included in other accrued liabilities at December 31, 2023 and March 31, 2023, respectively.

NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.

On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for a two million four hundred thousand dollars ($2,400,000) note payable. The intellectual property that was purchased requires further development prior to the product being finalized and produced so it has been expensed as research and development. The note payable is due within twelve (12) months of the date of the agreement and is included in current liabilities. If the Company has not raised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months of the agreement date, or a maximum of ten million dollars ($10,000,000) in investment, the seller will extend the payment for a further period of twelve (12) months for a 10% payment of the outstanding balance.

The Technology Platforms include but are not limited to:

Proteomic research platforms which include proprietary blends.

Combination design Techniques

Patent Pending Proprietary Blends

Patent Pending Formulas

Trademarks and all pending Trademarks

510K USA FDA, information and Know-how for application

All Clinical trials, (Right to use)

CE mark (International)

Regenerex Library formula incorporated in the Wound Healing Technology.

Wound Healing Technology QBX

Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.

Products:

Xcellderma over the counter product.

Accelerex, combination product as a drug device.

Accelerex in a tube.

NOTE 7 – COMMITMENTS AND CONTINGENCIES

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Related Party Asset Purchase Agreement. Payments made to the Company’s CEO and CFO in connection with the Asset Purchase Agreement are $43,500 and $0 during the nine-month period December 31, 2023 and December 31, 2022, respectively. The outstanding liability of $7,988 and $0 as at December 31, 2023 and March 31, 2023, respectively is included in other accrued liabilities.

NOTE 8 – OPERATING LEASES

On April 1, 2023, the Company entered into an office lease agreement commencing in May 2023 which expires on April 30, 2028. Under this agreement, the monthly rental payments are $1,650 throughout the term of the lease. The Company is required to pay for all utilities used on the premises and has paid a security deposit of $800 which is included in prepaid expenses.

On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920. To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures. We expect to launch production during the Company’s first quarter of our fiscal year ending March 31, 2025, and will notify the FDA to come into the plant for the inspection at that time. The Company is able to start production while the plant waits for the FDA Inspection. Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of each June from June 2023 to June 2027.

During the three and nine-month periods ended December 31, 2023, and 2022 the operating lease cost was $55,720 and $0 and $137,171 and $0 respectively and is included in general and administrative expenses in the accompanying financial statements.

NOTE 9 – STOCKHOLDERS’ DEFICIT

The Company has authorized the issuance of 675,000,000 shares of common stock with a par value of $0.001 per share.

During the nine months ended December 31, 2023, the Company issued 490,000 shares to board members and consultants for services rendered. Total stock-based compensation expense was $5,400 and $88,200 during the three and nine months ended December 31, 2023, respectively, in connection with these issuances based on the fair value of the stock on the respective grant dates.

During the nine months ended December 31, 2023, the Company issued 716,000 warrants to board members and consultants for services rendered with a total grant date fair value of $72,501. Total stock-based compensation expense of $66,434 was recorded in connection with these awards during the nine months ended December 31, 2023. The remaining stock-based compensation of approximately $6,070 will be recognized over the next six months. The warrants contain an exercise price of $0.33 per share, vesting terms ranging from immediately to June 30, 2024, and expire on dates ranging from July 1, 2029 to January 1, 2030.

The warrant fair values were estimated using a Black Scholes model with a 5-year expected term, risk-free interest rate ranging from 5.19% to 5.54%, a dividend yield of 0%, and a volatility of 80.0%. The risk-free interest rate assumptions for options granted is based upon observed interest rates on the United States government securities appropriate for the expected term of the equity awards.

As of the date of this valuation, the Companies stock was not trading. The volatility was calculated based on comparable public companies. The Company will continue to monitor peer companies and other relevant factors used to measure expected volatility for future equipment award grants, until such time that the Company’s Common Stock has enough market history to use historical volatility.

The dividend yield assumption for equity awards granted is based on Company’s history and expectation of dividend payouts. The Company has never declared or paid any cash dividends on its Common Stock, and the Company does not anticipate paying any cash dividends in the foreseeable future.

The closing stock price of the Company’s common stock is not available as the Company’s stock is not trading. As a result, the Board of Directors and management determined the fair value of the common stock to be $0.18 per share based upon an allocation of the recent cash price paid for common stock and warrants during the nine months ended December 31, 2023.

During the nine-month period ended December 31, 2023, the Company issued 343,250 shares of common stock with a par value of $0.001 for the price of one ($1) dollar per share for a total of for a total of $343,250. Five warrants were issued for each share purchased, for a total of 1,716,250 warrants. The warrants are exercisable at twenty ($0.20) cents and expire from April 2025 through September 2025.

As of December 31, 2023, 2,432,250 warrants had been issued of which 2,372,226 are vested. None of the warrants have been exercised.

NOTE 10 – SUBSEQUENT EVENTS

Subsequent to the nine-month period ended December 31, 2023, three additional notes to a shareholder that were originally due in January and February 2024 with a principal amount of approximately $75,000 US Funds ($101,500 Canadian Funds) were reissued in the principal amount of approximately $91,000 US Funds ($121,800 Canadian dollars) which included the original principal amount plus accrued interest of approximately $16,000 US Funds ($20,300 Canadian dollars). Repayment of the notes are due within six (6) months of the date of renewal.

Subsequent to the nine-month period ended December 31, 2023, one additional note to a shareholder that was originally due in February 2024 with a principal amount of $21,600 was reissued in the principal amount of $25,920 which included the original principal amount of $21,600 plus interest accrued in the amount of $4,320. Repayment of the note is due July 14, 2024.

Subsequent to the nine-month period ended December 31, 2023, we approved the issuance of fifty thousand (50,000) shares of common stock with a par value of $0.001 for the price of one ($1) dollar for a total of fifty thousand ($50,000) dollars. One warrant was issued for each share purchased, for a total of 50,000 warrants. The warrants are exercisable at one ($1) dollar per share and expire twenty-four (24) months after the date of the purchase agreement.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this Quarterly Report, “Company,” “our company,” “us,” and “our” refer to Regenerex Pharma, Inc., unless the context requires otherwise.

Forward-Looking Statements

The following information contains certain forward-looking statements. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “could,” “expect,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

Estimated COVID-19 impacts and uncertainties.

COVID-19 has severely impacted, and is expected to continue to impact, the economies of the U.S. and other countries around the world COVID-19 has created significant public health concerns as well as significant volatility, uncertainty, and economic disruption in every region in which we operate, all of which have adversely affected and may continue to adversely affect our industries and our business operations. Further, financial and credit markets have experienced and may again experience volatility.

Beginning in our first fiscal quarter of 2020, the novel coronavirus known as “COVID-19" began to spread throughout the world, resulting in a global pandemic. The pandemic triggered a significant downturn in global commerce as early as February 2020 and the challenging market conditions have continued throughout the second half of fiscal 2020 through 2021 and into the first half of fiscal 2022 and may continue for an extended period.

COVID-19 continued to affect global economic conditions during the nine months ended December 31, 2023. The Company expects this will continue in the Company’s fourth quarter. The situation surrounding COVID-19 remains fluid, and we are actively managing our response in collaboration with team members and business partners and assessing potential impacts to our financial position and operating results, as well as developments in our business.

Operations and New Developments

On November 15, 2021, the Company entered into an Related Party Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15^th of the following month, for a period of 60 months.

On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for a two million four hundred thousand dollars ($2,400,000) interest-free due August 17, 2024. The note payable is due within twelve (12) months of the date of the agreement. If the Company has not raised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months, or a maximum of ten million dollars ($10,000,000) in investment, the seller will extend the payments for a further period of twelve (12) months for a 10% payment of the outstanding balance.

The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.

Business of Issuer

The business of Regenerex Pharma, Inc., (the “Company” or “Regenerex Pharma,”), is to develop and market Woundcare Healing products. The Company has three technologies for different types of wound conditions:

•

The first is for closing chronic wounds,

•

the second is for accelerating closure of acute or surgical wounds, and

•

the third solves the issue on contamination of all types of wounds including the destruction of biofilms.

The current product technology provides the Company a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. and global markets.

Products:

Xcellderma OTC - Liquid Bandage Skin Protectant Xcellderma™ products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBx™ the active ingredient down regulates the production of certain proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds. Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).

Accelerex Sterile Wound Cream - The first commercially available medical device, Accelerex, is for the treatment of a wide variety of chronic and acute wounds. Accelerex is a custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated with an ointment containing QBx. Chronic wounds are generally defined as wounds that have not healed after thirty days of consistent clinical treatment, and include diabetic ulcers, burns, pressure ulcers (bedsores), and venous stasis ulcers. The Company’s broadly enabling technology was discovered from oak bark extract and referred to as QBx™.

Accelerex Impregnated Sterile Wound Dressing – For use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. FDA-cleared, prescription-only combination devices that blends the benefits of a would dressing with two drug components. Provides 3 modes of action to help trat acute and chronic wounds.: Protective dressing, moisturizing ointment, and 2 drug components: rubidium chloride and potassium chloride.

Regenerex System has been shown in many clinical trials to successfully close up to 95% of non-responding chronic wounds within 90 days. The wounds clinically tested had already been subject to current protocols of treatment and failed to heal. Competitive clinical trials indicated there isn’t another System that has the ability to close chronic wounds at these levels and speed. Not only does the System close chronic wounds relatively quickly but it does so at a very reasonable cost.

QBx™ contributes to setting up a suitable environment to allow wounds to close. Other than the products marketed by the Company, there are no products currently available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases. Other modern wound dressings such as hydrocolloids and collagens absorb wound fluids, but these dressings do not impact the cellular environment with simple gauze and gauze-like dressings to cover and protect the wound.

Our QBx™ technology is the most efficacious, and clinically proven Chronic wound Care product in the world. Chronic wounds are those that fail to progress through a normal, orderly, and timely sequence of repair. They are not only characterized by delayed healing for weeks, months, or even years, but also by a resistance to treatment with conventional dressings and therapies. They impart a particularly devastating financial and quality-of-life burden on individuals suffering from the wounds and are frustrating for the caregivers and clinicians who attempt to manage, but fail to heal, these wounds.

Non-healing chronic wounds are thought to be a consequence of factors that affect both the production of new tissue and the elevated destruction of existing tissue. Biochemically, these wounds appear to be stuck in a catabolic, inflammatory phase that is hostile to local growth factors and the activity of fibroblasts and keratinocytes. Increases in matrix metalloproteinases (MMPs) MMP-2 and MMP-9 are of significance in non-healing chronic wounds.

MMPs are a group of zinc-containing proteolytic enzymes that play an important role in the remodeling of the extracellular matrix of wounds. An overproduction of MMPs may result in degradation of the extracellular matrix and inactivation of vital growth factors. A precisely orchestrated balance of MMP production and their natural inhibitors (TIMPs) is needed.

Additionally, it is theorized that wounds stuck in the inflammatory phase persistently overproduce free radicals or reactive oxygen species (ROS). At low concentration and early in the inflammatory phase of wound healing, ROS such as hydrogen peroxide (H2O2), have a positive effect on healing through stimulation of fibroblast proliferation. However, persistent overproduction of ROS is thought to be detrimental to healing. A new treatment strategy has emerged focused upon manipulating the expression of genes which control the endogenous production of MMPs and TIMPs within the local wound environment. Contrary to modalities designed to sequester MMPs and/or act as a competitive substrate for protease activity, this technology strategy relies on delivery of metal ions into the wound to help regulate gene expression for the production of MMPs and TIMPs, thus bringing them into balance. These metal ions are delivered via a polyethylene glycol based, QBx™ ointment, which also contains citric acid to help normalize wound pH and reduce ROS activity. The QBx™ ointment is delivered via a tube or an acetylated regenerated cellulose carrier which allows for the passage of wound drainage and is non-fiber shedding. The entire composition is marketed as our primary wound dressing called Accelerex™.

Approximately 80% of chronic wounds display elevated levels of MMPs. Traditionally, however, these wounds have been managed with simple gauze and gauze-like dressings to cover and protect the wound. Other modern wound dressings such as hydrocolloids and collagens absorb wound fluids, but these dressings do not impact the cellular environment. This void in the treatment regimen offers a unique market advantage. QBx™ contributes to creating a suitable environment to allow wounds to close. These formularies are based on Proteases Down Regulating Technology and provide the System for a comprehensive suite of wound care products focused on the treatment of chronic wounds.

Chronic wounds impose significant costs to the US economy. Chronic wounds are a growing issue in the United States, causing immense patient pain and suffering as well as substantial economic and social cost. Although precise information on the prevalence of chronic wounds in the US is unavailable, it is estimated that, as of 2021, there were more than 8.3 million Americans suffering from chronic wounds. Chronic wounds are generally defined as wounds that have not healed after ninety days of consistent clinical treatment, and include diabetic foot ulcers, pressure ulcers (bedsores), and venous stasis ulcers, however this does not include acute wounds.

The most common chronic wounds are diabetic foot ulcers and pressure ulcers. The increasing number of Americans with diabetes and obesity we well as the aging population will likely cause the number of individuals with chronic wounds to continue to rise. In addition to the immeasurable human benefits of improving treatment outcomes, there would be substantial economic effect. The costs of medical treatment could be expected to decrease, and, as patients are able to return to work sooner, productivity would increase.

Due to the staggering costs associated with chronic wounds in the US, the Affordable Healthcare Act (AHA) is changing how the entire wound care system is reimbursed in the US. Now all four markets segments: hospital, nursing homes, home health, and general wound care clinics are all on paid on a “pay for performance basis.” These cost pressures in the healthcare system are a major issue in the wound care market, with the US government and payors seeking new approaches that address cost constraints and product performance. Home health is now paid on a “diagnostic code” for the wound in single payments removing the risk from the Payee to the Payer. The Company’s first markets will be those segments that are totally “at risk” for single payments to close the wounds. Today, the fastest growing segment in the US wound market is Home Health and Nursing Homes due to the aging population.

The Company has purchased proprietary wound care formulations, and has entered into an agreement, dated June 10, 2023, with Woundcare Labs, LLC to lease a plant and equipment in Tennessee. We expect to launch our sales initiative during the Company’s first quarter of our fiscal year ending March 31, 2025.

Currently management is engaged in developing managed care agreements with southeastern states to manage their Medicaid wound care patients. Regenerex would provide our wound care products and protocols which would result in a large savings for the state Medicaid population. The Company is also in the process of negotiating with several distributors in various Middle Eastern countries to provide the Company's products. The Company has engaged into an agreement as of June 11, 2023, in the amount of $45,000, with First Forte Consultancy in the UAE to assist in meetings and road shows, introducing potential clients for distribution of the companies wound care product. $22,500 was paid June 15, 2023, and the balance of $22,500 is to be paid after the road shows and meetings are completed, in the Company’s fourth quarter.

Financial Results and Trends

Results of Operations for the Three and Nine Months Ended December 31, 2023 and 2022

At present, the Company has $0 revenue during the nine months ended December 31, 2023, and 2022, respectively. Net loss increased from $49,400 to $263,976 for the three months ended December 31, 2022 to December 31, 2023 and from $91,040 to $3,251,000 for the nine months ended December 31, 2022 to December 31, 2023, due to the purchase of intellectual property which was recorded as research and development expenses due to the nature of the acquired IP, higher payroll expense and higher lease costs.

Liquidity and Capital Resources

The Company requires significant cash to launch its business and reduce its payables. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. The Company’s primary sources of liquidity and capital resources have been notes payable, which are not sufficient prospectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise additional capital in the near future or meet financing requirements, the Company may need to curtail or alter its plan of operations, seek additional capital on less favorable terms, and/or pursue other remedial measures.

Cash Flow

The following table summarizes, for the periods indicated, selected items in our condensed Statements of Cash Flows:

	Nine months Ended
	December 31,
	2023			2022
Net cash (used in) provided by:
Operating activities	$	(393,113	)	$	(73,140	)
Investing activities	$	(6,299	)	$	(1,398	)
Financing activities	$	406,133		$	73,101

Operating Activities

Cash used in operating activities was $393,113 and $73,140 for the nine months ended December 31, 2023 and 2022, respectively. The increase in cash used in operating activities was primarily due to an increase in net loss.

Investing Activities

Cash used in investing activities was $6,299 and $1,398 for the nine months ended December 31, 2023 and 2022. The increase in cash used in investing activities was due to the purchase of furniture and computer equipment.

Financing Activities

Cash provided by financing activities was $406,133 and $73,101 for the nine months ended December 31, 2023 and 2022, respectively. The increase in cash provided by financing activities was primarily due to proceeds from sale of common stocks and warrants and additional notes payable offset by repayment of notes payable.

Off-Balance Sheet Arrangements

None.

WHERE YOU CAN FIND MORE INFORMATION

You are advised to read this Quarterly Report on Form 10-Q in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Registration Statement on Form 10-12G, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We had no material changes in market risk from those described in “Item 2—Quantitative and Qualitative Disclosures about Market Risk” of our Annual Report on Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

This report includes the certification of our Chief Executive Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations revered to in those certifications.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC”) rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

Under the supervision and with the participation of management, including the principal executive officer and principal financial officer, the Company conducted an evaluation of the effectiveness of internal control over financial reporting. This assessment was based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation under the framework in Internal Control – Integrated Framework, management concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2023, as such term is defined in Exchange Act Rule 13a-15(f).

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives.

As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer need to carry out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2023.

Management’s Report on Internal Control over Financial Reporting

Our Chief Executive Officer and the Chief Financial Officer are responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of our internal control over financial reporting. Internal control over financial reporting (as defined in Rules 13a-15(f) and 15d(f) under the Exchange Act) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. GAAP. Internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets, (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (c) provide reasonable assurance that receipts and expenditures are being made only in accordance with appropriate authorization of management and the Board of Directors, and (d) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the financial statements.

In connection with the preparation of this Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, our Chief Executive Officer and Chief Financial Officer have concluded that our internal controls and procedures over financial reporting were not effective and that material weaknesses existed in the following area as of December 31, 2023.

We do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding complex and non-routine transactions. Management recognized that during the preparation of our Financial Statements, the Company recorded material post close adjustment This situation led to delays in the process and evidenced the need to improve the existent control environment including the experience and knowledge of the team. Management will continue to seek guidance from third-party experts and consultants to gain a thorough understanding of these transactions.

Our management will continue to monitor and evaluate the designation, implementation and effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implement additional enhancements or improvements, as necessary.

Inherent Limitations on Internal Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the control system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Limitations inherent in any control system include the following:

	●	Judgments in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes;

	●	Controls can be circumvented by individuals, acting alone or in collusion with others, or by management override;

	●	The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions;

	●	Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures; and

	●	The design of a control system must reflect the fact that resources are constrained, and the benefits of controls must be considered relative to their costs.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of December 31, 2023, the Company is not involved in any material litigation.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS SECURITIES

During the nine months ended December 31, 2023, Regenerex did not sell any unregistered equity securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINING SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

There is no information with respect to which information is not otherwise called for by this form.

ITEM 6. EXHIBITS

Exhibits

3.0	Articles of Incorporation. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

3.1	Amended Articles of Incorporation. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

3.2	Amended Articles of Incorporation. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

3.3	Corporate Bylaws. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

10.1	Advance from Shareholder of Regenerex Pharma, Inc. Incorporated by reference to the Registrant’s Form 10-12G filed on July 28, 2017.

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act

32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant	Regenerex Pharma, Inc.

Date: February 5, 2024	By:	/s/ Gregory Pilant
	Gregory Pilant
	Chief Executive Officer

Exhibit 31.1

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934 for the period ending December 31, 2023

I, Gregory Pilant, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Regenerex Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Registrant	Regenerex Pharma, Inc.

Date: February 5, 2024	By:	/s/ Gregory Pilant
	Gregory Pilant
	Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

I, Deborah Pilant, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Regenerex Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Registrant	Regenerex Pharma, Inc.

Date: February 5, 2024	By:	/s/ Deborah Pilant
	Deborah Pilant
	Chief Financial Officer (Principal Financial Officer)

Exhibit 32.1

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Regenerex Pharma, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Gregory Pilant, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Registrant	Regenerex Pharma, Inc.

Date : February 5, 2024	By:	/s/ Gregory Pilant
	Gregory Pilant
	Chief Executive Officer (Principal Executive Officer)

Exhibit 32.2

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Regenerex Pharma, Inc. (the ‘Company’) on Form 10-Q for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the ‘Report’), I, Irene Getty, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Registrant	Regenerex Pharma, Inc.

Date: February 5, 2024	By:	/s/ Deborah Pilant
	Deborah Pilant
	Chief Financial Officer (Principal Financial Officer)

Cover - shares	9 Months Ended
Cover - shares	Dec. 31, 2023	Feb. 05, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--03-31
Entity File Number	000-53230
Entity Registrant Name	REGENEREX PHARMA, INC.
Entity Central Index Key	0001357878
Entity Tax Identification Number	98-0479983
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5348 Vegas Drive #177
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	877
Local Phone Number	761-7479
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		277,995,910

BALANCE SHEETS (UNAUDITED) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current Assets
Cash and equivalents	$ 7,856	$ 1,135
Prepaid expenses	1,423
Total Current Assets	9,279	1,135
Website, net of accumulated amortization of $28,557 and $26,397, respectively	2,043	4,203
Furniture and computer equipment, net of accumulated amortization of $1,170 and $197, respectively	6,527	1,201
Right of use asset	834,293
Total Assets	852,142	6,539
Current Liabilities
Accounts payable	78,950	75,145
Related party advances	4,757	131,887
Accrued compensation	414,962	221,192
Other accrued liabilities	83,227	125,787
Current portion of notes payable to shareholder	322,246	222,771
Current portion of notes payable to related parties	103,500
Current portion of notes payable	2,400,000
Current portion of lease liabilities	152,046
Total Current Liabilities	3,559,688	776,782
Notes payable to shareholder, net of current portion	260,788	314,704
Notes payable to related parties, net of current portion		38,000
Notes payable, net of current portion	184,232
Lease liabilities, net of current portion	723,497
Total Liabilities	4,728,205	1,129,486
Commitments and Contingencies (Note 7)
Stockholders’ Deficit
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,945,910 and 277,112,660 issued and outstanding at December 31, 2023 and March 31, 2023, respectively	277,946	277,113
Additional paid-in capital	1,169,014	671,963
Accumulated deficit	(5,323,023)	(2,072,023)
Total Stockholders’ Deficit	(3,876,063)	(1,122,947)
Total Liabilities and Stockholders’ Deficit	$ 852,142	$ 6,539

BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 28,557	$ 26,397
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 1,170	$ 197
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	675,000,000	675,000,000
Common Stock, Shares, Issued	277,945,910	277,112,660
Common Stock, Shares, Outstanding	277,945,910	277,112,660

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses
General and administrative	$ 239,384	$ 29,102	$ 785,481	$ 67,892
Research and development			2,400,000
Total Operating Expenses	239,384	29,102	3,185,481	67,892
Operating Loss	(239,384)	(29,102)	(3,185,481)	(67,892)
Other Income (Expense)
Interest expense	(20,219)	(17,241)	(58,526)	(49,365)
Foreign currency gain (loss)	(4,373)	(3,057)	(6,993)	26,217
Total Other Income (Expense)	(24,592)	(20,298)	(65,519)	(23,148)
Net Loss	$ (263,976)	$ (49,400)	$ (3,251,000)	$ (91,040)
Basic and Diluted Loss per Common Share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.00)
Weighted Average Number of Common Shares Outstanding	277,919,497	227,112,660	277,539,983	277,112,660

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities:
Net loss	$ (3,251,000)	$ (91,040)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	3,133	2,598
Foreign currency adjustments	6,993	(26,217)
Stock-based compensation	154,634
Research and development	2,400,000
Amortization of ROU assets, net of liabilities	41,250
Changes in operating assets and liabilities:
Prepaid expenses	(1,423)	2,756
Accounts payable and accrued liabilities	253,300	38,763
Net cash used in operating activities	(393,113)	(73,140)
Cash Flows from Investing Activities:
Purchase of furniture and computer equipment	(6,299)	(1,398)
Net cash used in investing activities	(6,299)	(1,398)
Cash Flows from Financing Activities:
Related party advances	4,557	200
Partial repayment of note payable to shareholder	(10,000)
Partial repayment of note payable to related parties	(39,500)	(2,500)
Proceeds from sale of common stock and warrants	343,250
Net cash provided by financing activities	406,133	73,101
Increase (Decrease) in cash and equivalents	6,721	(1,437)
Cash and cash equivalents, beginning of period	1,135	2,640
Cash and cash equivalents, end of period	7,856	1,203
Supplemental Cash Flow Information – Cash Paid For:
Income Taxes
Interest
Non-Cash Investing and Financing Activities:
Accrued interest converted into note payable	98,744	7,211
Operating lease, ROU asset and liabilities	953,535
Note payable issued for acquisition of intellectual property	2,400,000
Other Affiliates [Member]
Cash Flows from Financing Activities:
Proceeds from notes payable to related parties	2,826	34,901
Affiliated Entity [Member]
Cash Flows from Financing Activities:
Proceeds from notes payable to related parties	$ 105,000	$ 40,500

STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2022	$ 277,113	$ 671,963	$ (1,934,693)	$ (985,617)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022	277,112,660
Net loss			(41,640)	(41,640)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022	277,112,660
Ending balance, value at Sep. 30, 2022	$ 277,113	671,963	(1,976,333)	(1,027,257)
Beginning balance, value at Mar. 31, 2022	$ 277,113	671,963	(1,934,693)	(985,617)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022	277,112,660
Net loss				(91,040)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2022	277,112,660
Ending balance, value at Dec. 31, 2022	$ 277,113	671,963	(2,025,733)	(1,076,657)
Beginning balance, value at Sep. 30, 2022	$ 277,113	671,963	(1,976,333)	(1,027,257)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2022	277,112,660
Net loss			(49,400)	(49,400)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2022	277,112,660
Ending balance, value at Dec. 31, 2022	$ 277,113	671,963	(2,025,733)	(1,076,657)
Beginning balance, value at Mar. 31, 2023	$ 277,113	671,963	(2,072,023)	$ (1,122,947)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023	277,112,660			277,112,660
Net loss			$ (2,987,024)	$ (2,987,024)
Shares and warrants sold for cash	343	342,907		343,250
Stock-based compensation	$ 460	$ 132,928		$ 133,388
Stock Issued During Period, Shares, Issued for Services				460,000
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023	277,915,910
Ending balance, value at Sep. 30, 2023	$ 277,916	1,147,798	(5,059,047)	$ (3,633,333)
Beginning balance, value at Mar. 31, 2023	$ 277,113	671,963	(2,072,023)	$ (1,122,947)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023	277,112,660			277,112,660
Net loss				$ (3,251,000)
Shares and warrants sold for cash				343,250
Stock-based compensation				$ 343,250
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2023	277,945,910			277,945,910
Ending balance, value at Dec. 31, 2023	$ 277,946	1,169,014	(5,323,023)	$ (3,876,063)
Beginning balance, value at Sep. 30, 2023	$ 277,916	1,147,798	(5,059,047)	(3,633,333)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2023	277,915,910
Net loss			(263,976)	$ (263,976)
Shares and warrants sold for cash				30,000
Stock-based compensation	$ 30	21,216		$ 21,246
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2023	277,945,910			277,945,910
Ending balance, value at Dec. 31, 2023	$ 277,946	$ 1,169,014	$ (5,323,023)	$ (3,876,063)

NATURE OF OPERATIONS

9 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1 – NATURE OF OPERATIONS

Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.

Risks and Uncertainties

The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.

BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

9 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

GOING CONCERN

9 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3 – GOING CONCERN

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Earnings per Share

Website

Furniture and Computer Equipment

Right of Use Assets and Lease Liabilities

Stock-Based Compensation

Research and Development

Recent Accounting Pronouncements

RELATED PARTY TRANSACTIONS

9 Months Ended

Dec. 31, 2023

RELATED PARTY TRANSACTIONS

NOTE 5 – RELATED PARTY TRANSACTIONS

The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6).

Related Party Advances

The related party advances totaled $4,757 and $131,887 as of December 31, 2023, and March 31, 2023, respectively.

Notes Payable to Related Parties

Note Payables to Shareholders

The reissued notes are unsecured, bear interest at 10% per annum, and have revised maturity dates ranging from April 11, 2024, to June 17, 2025.

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY

The Technology Platforms include but are not limited to:

Proteomic research platforms which include proprietary blends.

Combination design Techniques

Patent Pending Proprietary Blends

Patent Pending Formulas

Trademarks and all pending Trademarks

510K USA FDA, information and Know-how for application

All Clinical trials, (Right to use)

CE mark (International)

Regenerex Library formula incorporated in the Wound Healing Technology.

Wound Healing Technology QBX

Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark.

Products:

Xcellderma over the counter product.

Accelerex, combination product as a drug device.

Accelerex in a tube.

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

OPERATING LEASES

9 Months Ended

Dec. 31, 2023

Operating Leases

OPERATING LEASES

NOTE 8 – OPERATING LEASES

STOCKHOLDERS’ DEFICIT

9 Months Ended

Dec. 31, 2023

Equity [Abstract]

STOCKHOLDERS’ DEFICIT

NOTE 9 – STOCKHOLDERS’ DEFICIT

The Company has authorized the issuance of 675,000,000 shares of common stock with a par value of $0.001 per share.

As of December 31, 2023, 2,432,250 warrants had been issued of which 2,372,226 are vested. None of the warrants have been exercised.

SUBSEQUENT EVENTS

9 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran’s administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.
Earnings per Share	Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. During the three and nine-months ended December 31, 2023, the Company excluded the outstanding stock warrants from its calculation of earnings per share, as the warrants would be anti-dilutive. As at December 31, 2023 and 2022, the Company had common shares warrants outstanding of 2,432,250 and 0, respectively.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2023 and 2022 was $723 and $723 and $2,160 and $1,016, respectively.
Furniture and Computer Equipment	Furniture and Computer Equipment Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the three and nine months ended December 31, 2023 and 2022 was $435 and $82 and $973 and $82, respectively. Significant betterments are capitalized while purchases under $500 are expensed as incurred.
Right of Use Assets and Lease Liabilities	Right of Use Assets and Lease Liabilities The Company has active operating lease arrangements for office space, production equipment, and production facilities. The Company is required to make fixed minimum rent payments relating to its right to use the underlying leased asset. In accordance with the adoption of ASC 842, the Company recorded right-of-use assets and related lease liabilities for these leases as of December 2023. The Company’s lease agreements do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an incremental borrowing rate of 10% to discount each of its lease liabilities based on the remining lease term.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is measured at the grant date, based on the estimated fair value of the award. Stock-based compensation is recognized as expense over the employee’s requisite vesting period and over the nonemployee’s period of providing goods or services. The fair value of each stock warrant is estimated on the date of grant using the Black-Scholes option valuation model. Share grants are measured based on the fair market value of the underlying stock on the grant date.
Research and Development	Research and Development We incur research and development costs during the process of researching and developing additional technologies purchased and future manufacturing processes. Our research and development costs consist primarily of the purchase of additional intellectual property that we will use in the development of our planned product. We expense these costs as incurred until the resulting product has been completed, tested, and made ready for commercial use.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NATURE OF OPERATIONS (Details Narrative) - USD ($)	3 Months Ended
NATURE OF OPERATIONS (Details Narrative) - USD ($)	Dec. 31, 2023	Nov. 15, 2021
Entity Incorporation, Date of Incorporation	Nov. 18, 2005
Asset Acquisition, Contingent Consideration, Liability		$ 10,000,000
Purchase Intellectual Property [Member]
Shares, Issued		150,000,000

GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Equity, Attributable to Parent	$ 3,876,063	$ 3,633,333	$ 1,122,947	$ 1,076,657	$ 1,027,257	$ 985,617

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Class of Warrant or Right, Outstanding	2,432,250	0	2,432,250	0
Finite-Lived Intangible Asset, Useful Life	3 years		3 years
Amortization of Intangible Assets	$ 723	$ 723	$ 2,160	$ 1,016
Other Depreciation and Amortization	$ 435	$ 82	$ 973	$ 82
Lessee, Finance Lease, Discount Rate	10.00%		10.00%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years		5 years

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023	Sep. 30, 2022
Related Party Transaction [Line Items]
Related Party Transaction, Rate	10.00%
[custom:RelatedPartyAdvances-0]	$ 4,757		$ 4,757		$ 131,887
Interest Expense	20,219	$ 17,241	58,526	$ 49,365
[custom:NotesPayableRelatedParties-0]	103,500		103,500
[custom:NotesPayableToRelatedPartiesNetOfCurrentPortion-0]					38,000
Interest Expense, Debt			2,443	890
Notes Payable	184,232		184,232
Accrued Liabilities, Current	83,227		83,227		125,787
Aggregate Interest Expense [Member]
Related Party Transaction [Line Items]
Accrued Liabilities, Current	67,537		67,537			$ 51,892
Reissued Notes [Member]
Related Party Transaction [Line Items]
Notes Payable	154,000		154,000
Long-Term Debt, Gross	185,000		185,000
Interest Payable, Current	31,000		31,000
Reissued Notes 2 [Member]
Related Party Transaction [Line Items]
Notes Payable	67,400		67,400
Long-Term Debt, Gross	82,735		82,735
Interest Payable, Current	15,335		15,335
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	131,687		131,687
[custom:RelatedPartyAdvances-0]	52,545		52,545
Affiliates [Member]
Related Party Transaction [Line Items]
Interest Expense			3,285	9,922
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
[custom:RelatedPartyAdvances-0]	4,557	$ 200	4,557	200
Chief Executive Officer And Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	105,000		$ 105,000		40,500
Repayments of Notes Payable				$ 2,500
Debt Instrument, Interest Rate During Period			10.00%
Chief Executive Officer And Chief Financial Officer [Member] \| Period Year Ended Mar 312023 [Member]
Related Party Transaction [Line Items]
Repayments of Notes Payable			$ 38,000
Chief Executive Officer And Chief Financial Officer [Member] \| Nine Month Period Ended December 312023 [Member]
Related Party Transaction [Line Items]
Repayments of Notes Payable			1,500
Majority Shareholder [Member]
Related Party Transaction [Line Items]
Notes and Loans Payable	583,034		583,034		$ 537,475
Shareholder [Member] \| Promissory 1 Notes [Member]
Related Party Transaction [Line Items]
Notes Payable, Noncurrent	$ 2,800		$ 2,800
Debt Instrument, Interest Rate, Stated Percentage	1000.00%		1000.00%

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)	1 Months Ended
	Nov. 15, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Business Combination, Contingent Consideration Arrangements, Description	up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023	Nov. 15, 2021
Assets Sold under Agreements to Repurchase [Line Items]
Asset Acquisition, Contingent Consideration, Liability						$ 10,000,000
General and Administrative Expense	$ 239,384	$ 29,102	$ 785,481	$ 67,892
Accrued Liabilities, Current	83,227		83,227		$ 125,787
Asset Purchase Agreement Liability [Member]
Assets Sold under Agreements to Repurchase [Line Items]
Accrued Liabilities, Current	7,988		$ 7,988		0
Chief Executive Officer And Chief Financial Officer [Member]
Assets Sold under Agreements to Repurchase [Line Items]
General and Administrative Expense	$ 43,500				$ 0

OPERATING LEASES (Details Narrative) - USD ($)	3 Months Ended
OPERATING LEASES (Details Narrative) - USD ($)	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023
Lessee, Lease, Description [Line Items]
Prepaid Expense, Current	$ 1,423
Lessee, Operating Lease, Description	On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920. To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures. We expect to launch production during the Company’s first quarter of our fiscal year ending March 31, 2025, and will notify the FDA to come into the plant for the inspection at that time. The Company is able to start production while the plant waits for the FDA Inspection. Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of each June from June 2023 to June 2027.
Office Lease [Member] \| Monthly Rental Payments [Member]
Lessee, Lease, Description [Line Items]
Operating Leases, Future Minimum Payments Due	$ 1,650
Office Lease [Member] \| Security Deposit [Member]
Lessee, Lease, Description [Line Items]
Prepaid Expense, Current	800
Plant Facility [Member]
Lessee, Lease, Description [Line Items]
Capital Lease Obligations, Current		$ 7,920
Plant Facility [Member] \| Monthly Rental Payments [Member]
Lessee, Lease, Description [Line Items]
Operating Leases, Future Minimum Payments Due	$ 18,000

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Common Stock, Shares Authorized	675,000,000		675,000,000		675,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001
Stock Issued During Period, Shares, Issued for Services		460,000
Share-Based Payment Arrangement, Noncash Expense			$ 154,634
Class of Warrant or Right, Outstanding	2,432,250		2,432,250	0
Sale of Stock, Price Per Share	$ 0.18		$ 0.18
Stock Issued During Period, Shares, New Issues	30,000	343,250	343,250
Stock Issued During Period, Value, New Issues	$ 21,246		$ 343,250
Temporary Equity, Contract Terms	Five warrants were issued for each share purchased, for a total of 1,716,250 warrants. The warrants are exercisable at twenty ($0.20) cents and expire from April 2025 through September 2025.
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	2,372,226
Board Members And Consultants [Member] \| Services Rendered [Member]
Defined Benefit Plan Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services			490,000
Share-Based Payment Arrangement, Noncash Expense	$ 5,400		$ 88,200
Class of Warrant or Right, Outstanding	716,000		716,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 72,501		$ 72,501
[custom:StockBasedCompensationUnrecognizedCompensationCost-0]	$ 6,070		$ 6,070
Board Members And Consultants [Member] \| Services Rendered [Member] \| Warrants [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.33		$ 0.33

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jan. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Subsequent Event [Line Items]
Notes Payable		$ 184,232
Common Stock, Shares, Issued		277,945,910	277,112,660
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Reissued Notes 2 [Member]
Subsequent Event [Line Items]
Notes Payable		$ 67,400
Long-Term Debt, Gross		82,735
Interest Payable, Current		$ 15,335
Subsequent Event [Member] \| Reissued Notes 1 [Member]
Subsequent Event [Line Items]
Notes Payable	$ 75,000
Long-Term Debt, Gross	91,000
Debt Instrument, Issued, Principal	16,000
Subsequent Event [Member] \| Reissued Notes 2 [Member]
Subsequent Event [Line Items]
Notes Payable	21,600
Long-Term Debt, Gross	25,920
Debt Instrument, Issued, Principal	21,600
Interest Payable, Current	$ 4,320
Debt Instrument, Maturity Date	Jul. 14, 2024
Subsequent Event [Member] \| Share Issuance 1 [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued	50,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Stock Issued During Period, Value, Other	$ 50,000
Debt Conversion, Description	One warrant was issued for each share purchased, for a total of 50,000 warrants. The warrants are exercisable at one ($1) dollar per share and expire twenty-four (24) months after the date of the purchase agreement.

Regenerex Pharma (PK) (USOTC:RGPX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Click aqui para mais gráficos Regenerex Pharma (PK).

Regenerex Pharma (PK) (USOTC:RGPX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024

	Cotações em Tempo Real	Book de Ofertas
Bovespa (B3)
BM&F
Índices da Dow Jones
New York Stock Exchange
NASDAQ
American Stock Exchange
Forex
Precious Metal

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

RGPX Regenerex Pharma Inc (PK)

Notícias Regenerex Pharma Inc (PK)

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo

Tendências Agora

Rankings

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

RGPX Regenerex Pharma Inc (PK)

Notícias Regenerex Pharma Inc (PK)

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo

BLACK FRIDAY

Economize até 50%* para TRADER PLUS

1 ano 30%, 2 anos 40% e *3 anos 50%